Inhibiteurs de la cyclooxygénase 2 : Questions médicales fréquentes
Nom anglais: Cyclooxygenase 2 Inhibitors
Descriptor UI:D052246
Tree Number:D27.505.954.329.030.500.500
Termes MeSH sélectionnés :
Surveys and Questionnaires
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteurs de la cyclooxygénase 2 : Questions médicales les plus fréquentes",
"headline": "Inhibiteurs de la cyclooxygénase 2 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteurs de la cyclooxygénase 2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-12",
"dateModified": "2025-04-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la cyclooxygénase 2"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inhibiteurs des cyclooxygénases",
"url": "https://questionsmedicales.fr/mesh/D016861",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des cyclooxygénases",
"code": {
"@type": "MedicalCode",
"code": "D016861",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.329.030.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs de la cyclooxygénase 2",
"alternateName": "Cyclooxygenase 2 Inhibitors",
"code": {
"@type": "MedicalCode",
"code": "D052246",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Afshin Zarghi",
"url": "https://questionsmedicales.fr/author/Afshin%20Zarghi",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran."
}
},
{
"@type": "Person",
"name": "Rui Wang",
"url": "https://questionsmedicales.fr/author/Rui%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China."
}
},
{
"@type": "Person",
"name": "Mahsa Azami Movahed",
"url": "https://questionsmedicales.fr/author/Mahsa%20Azami%20Movahed",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran."
}
},
{
"@type": "Person",
"name": "Mohammad Mahboubi-Rabbani",
"url": "https://questionsmedicales.fr/author/Mohammad%20Mahboubi-Rabbani",
"affiliation": {
"@type": "Organization",
"name": "Islamic Azad University, Tehran Department of Medicinal Chemistry Tehran Iran."
}
},
{
"@type": "Person",
"name": "Ying Wang",
"url": "https://questionsmedicales.fr/author/Ying%20Wang",
"affiliation": {
"@type": "Organization",
"name": "College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Current treatment status of IgA nephropathy in Japan: a questionnaire survey.",
"datePublished": "2023-08-30",
"url": "https://questionsmedicales.fr/article/37646957",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10157-023-02396-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Questionnaire survey of healthcare professionals on taxane-induced nail change in Japan.",
"datePublished": "2024-09-10",
"url": "https://questionsmedicales.fr/article/39251506",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00520-024-08858-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "[The Questionnaire Survey of Japanese Practice and Environment for Targeted Radionuclide Therapy in 2021].",
"datePublished": "2023-01-25",
"url": "https://questionsmedicales.fr/article/36696976",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.6009/jjrt.2023-1317"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sequential dependencies of responses in a questionnaire survey and their effects on the reliability and validity of measurement.",
"datePublished": "2022-09-09",
"url": "https://questionsmedicales.fr/article/36085546",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3758/s13428-022-01943-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Issues in the Adoption of Online Medical Care: Cross-Sectional Questionnaire Survey.",
"datePublished": "2024-11-01",
"url": "https://questionsmedicales.fr/article/39486019",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2196/64159"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Utilisations thérapeutiques",
"item": "https://questionsmedicales.fr/mesh/D045506"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antirhumatismaux",
"item": "https://questionsmedicales.fr/mesh/D018501"
},
{
"@type": "ListItem",
"position": 6,
"name": "Anti-inflammatoires non stéroïdiens",
"item": "https://questionsmedicales.fr/mesh/D000894"
},
{
"@type": "ListItem",
"position": 7,
"name": "Inhibiteurs des cyclooxygénases",
"item": "https://questionsmedicales.fr/mesh/D016861"
},
{
"@type": "ListItem",
"position": 8,
"name": "Inhibiteurs de la cyclooxygénase 2",
"item": "https://questionsmedicales.fr/mesh/D052246"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteurs de la cyclooxygénase 2 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteurs de la cyclooxygénase 2",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteurs de la cyclooxygénase 2",
"description": "Comment diagnostiquer une inflammation nécessitant des COX-2 ?\nQuels tests sont utilisés pour évaluer l'efficacité des COX-2 ?\nLes COX-2 sont-ils prescrits pour toutes les douleurs ?\nComment différencier les douleurs inflammatoires des autres ?\nQuels signes cliniques indiquent l'utilisation des COX-2 ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Surveys+and+Questionnaires&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteurs de la cyclooxygénase 2",
"description": "Quels symptômes traitent les inhibiteurs de COX-2 ?\nLes COX-2 soulagent-ils la fièvre ?\nQuels effets secondaires peuvent survenir avec les COX-2 ?\nLes COX-2 affectent-ils l'humeur ?\nPeut-on ressentir des douleurs abdominales avec les COX-2 ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Surveys+and+Questionnaires&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteurs de la cyclooxygénase 2",
"description": "Comment prévenir les effets secondaires des COX-2 ?\nY a-t-il des mesures préventives avant de commencer les COX-2 ?\nLes patients à risque doivent-ils éviter les COX-2 ?\nComment surveiller l'efficacité des COX-2 ?\nLes changements de mode de vie aident-ils avec les COX-2 ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Surveys+and+Questionnaires&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteurs de la cyclooxygénase 2",
"description": "Quels médicaments sont des inhibiteurs de COX-2 ?\nComment les COX-2 sont-ils administrés ?\nLes COX-2 peuvent-ils être combinés avec d'autres médicaments ?\nQuelle est la durée du traitement avec les COX-2 ?\nLes COX-2 sont-ils disponibles sans ordonnance ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Surveys+and+Questionnaires&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteurs de la cyclooxygénase 2",
"description": "Quelles complications peuvent survenir avec les COX-2 ?\nLes COX-2 augmentent-ils le risque d'accidents vasculaires ?\nComment gérer les complications des COX-2 ?\nLes complications sont-elles fréquentes avec les COX-2 ?\nQuels signes indiquent une complication avec les COX-2 ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Surveys+and+Questionnaires&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteurs de la cyclooxygénase 2",
"description": "Quels facteurs augmentent le risque d'effets secondaires des COX-2 ?\nL'âge influence-t-il le risque avec les COX-2 ?\nLes femmes enceintes peuvent-elles utiliser des COX-2 ?\nLe tabagisme affecte-t-il l'utilisation des COX-2 ?\nLes antécédents familiaux influencent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D052246?mesh_terms=Surveys+and+Questionnaires&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une inflammation nécessitant des COX-2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur l'examen clinique et des tests d'imagerie pour évaluer l'inflammation."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité des COX-2 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des échelles de douleur et des tests fonctionnels peuvent être utilisés pour évaluer l'efficacité."
}
},
{
"@type": "Question",
"name": "Les COX-2 sont-ils prescrits pour toutes les douleurs ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils sont généralement prescrits pour des douleurs inflammatoires spécifiques comme l'arthrite."
}
},
{
"@type": "Question",
"name": "Comment différencier les douleurs inflammatoires des autres ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les douleurs inflammatoires sont souvent accompagnées de raideur matinale et d'enflure."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent l'utilisation des COX-2 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme l'enflure, la chaleur et la douleur persistante peuvent indiquer leur utilisation."
}
},
{
"@type": "Question",
"name": "Quels symptômes traitent les inhibiteurs de COX-2 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils traitent principalement la douleur et l'inflammation associées à des conditions comme l'arthrite."
}
},
{
"@type": "Question",
"name": "Les COX-2 soulagent-ils la fièvre ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les inhibiteurs de COX-2 ne sont pas principalement utilisés pour traiter la fièvre."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir avec les COX-2 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent des troubles gastro-intestinaux, des maux de tête et des vertiges."
}
},
{
"@type": "Question",
"name": "Les COX-2 affectent-ils l'humeur ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils ne sont pas connus pour affecter directement l'humeur, mais la douleur chronique peut le faire."
}
},
{
"@type": "Question",
"name": "Peut-on ressentir des douleurs abdominales avec les COX-2 ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs abdominales peuvent survenir en raison d'effets secondaires gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets secondaires des COX-2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pour prévenir les effets secondaires, il est conseillé de les prendre avec de la nourriture et de suivre les doses prescrites."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives avant de commencer les COX-2 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un bilan de santé et une évaluation des antécédents médicaux sont recommandés."
}
},
{
"@type": "Question",
"name": "Les patients à risque doivent-ils éviter les COX-2 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients avec des antécédents de problèmes cardiaques doivent consulter un médecin avant de les utiliser."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité des COX-2 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance peut inclure des évaluations régulières de la douleur et des tests de laboratoire."
}
},
{
"@type": "Question",
"name": "Les changements de mode de vie aident-ils avec les COX-2 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut améliorer l'efficacité des traitements anti-inflammatoires."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont des inhibiteurs de COX-2 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des exemples incluent le célécoxib et le rofécoxib, utilisés pour traiter l'inflammation."
}
},
{
"@type": "Question",
"name": "Comment les COX-2 sont-ils administrés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont généralement administrés par voie orale sous forme de comprimés ou de capsules."
}
},
{
"@type": "Question",
"name": "Les COX-2 peuvent-ils être combinés avec d'autres médicaments ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, mais il est important de consulter un médecin pour éviter les interactions médicamenteuses."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement avec les COX-2 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée dépend de la condition traitée, mais elle doit être déterminée par un médecin."
}
},
{
"@type": "Question",
"name": "Les COX-2 sont-ils disponibles sans ordonnance ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les inhibiteurs de COX-2 nécessitent généralement une prescription médicale."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les COX-2 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications peuvent inclure des problèmes gastro-intestinaux, des troubles cardiaques et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les COX-2 augmentent-ils le risque d'accidents vasculaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains inhibiteurs de COX-2 peuvent augmenter le risque d'accidents vasculaires cérébraux."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications des COX-2 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une consultation médicale et un ajustement du traitement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes avec les COX-2 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications ne sont pas fréquentes, mais elles peuvent survenir chez certains patients à risque."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication avec les COX-2 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des douleurs thoraciques, des saignements gastro-intestinaux ou des éruptions cutanées doivent alerter."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'effets secondaires des COX-2 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de maladies cardiaques, d'ulcères ou d'allergies augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque avec les COX-2 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent avoir un risque accru d'effets secondaires et de complications."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes peuvent-elles utiliser des COX-2 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'utilisation des COX-2 pendant la grossesse doit être évitée sauf si prescrite par un médecin."
}
},
{
"@type": "Question",
"name": "Le tabagisme affecte-t-il l'utilisation des COX-2 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut augmenter le risque de complications gastro-intestinales avec les COX-2."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies cardiaques peuvent augmenter le risque d'effets secondaires."
}
}
]
}
]
}
In 2020, the Committee of Clinical Practical Guideline for IgA Nephropathy (IgAN) revised the clinical practice guidelines. Herein, we conducted a questionnaire survey to assess the potential discrepa...
A web-based survey of members of the Japanese Society of Nephrology was conducted between November 15 and December 28, 2021....
A total of 217 members (internal physicians: 203, pediatricians: 14) responded to the questionnaire. Of these respondents, 94.0% answered that the clinical practice guidelines were referred to "always...
Our questionnaire survey revealed real-world aspects of IgAN treatment in Japan....
Taxanes are widely used chemotherapeutic agents that frequently cause nail changes and have a significant impact on patients' quality of life. Despite the prevalence of taxane-induced nail toxicity, l...
The questions addressed prophylactic methods, evaluation practices, and treatment approaches for various nail disorders. The questionnaires were distributed on March 1, 2022, with a response deadline ...
Of the 120 questionnaires distributed, 88 (73.3%) were returned, and all of them were analyzed. The respondents included 69 physicians (32 oncologists, 26 breast surgeons, 6 dermatologists, 3 obstetri...
Our survey revealed that the management of chemotherapy-induced nail changes varies in clinical practice in Japan. These findings emphasize the need for standardized management strategies and further ...
Recently, the targeted radionuclide therapy (TRT) was urgently required to adapt the practice and environment because of the implementation of novel therapeutic radiopharmaceuticals such as alpha- and...
The massive questionnaire survey, 2 months from October to November 2021, was conducted among nationwide 251 facilities that have performed TRT in the past two years. The alpha- and beta- therapeutic ...
The survey response rate was 69.1% (174 facilities). About 75% of these facilities reported that they either follow the guidelines or take their own measures to reduce occupational exposure. The confi...
We clarified the Japanese problem for TRT practice and environment by the questionnaire survey. Our findings indicated that the Japanese guidelines and manuals for TRT were not partly followed in the ...
The reliability and validity of measurements in questionnaire surveys are affected by the survey design. Previous studies have discussed whether the items on a multidimensional scale should be grouped...
Telemedicine, or online medical care, has gained considerable attention worldwide. However, it has not been widely adopted in Japan, and the detailed status of received and provided online medical car...
This study aims to investigate the current status of online medical care in Japan and the factors limiting its adoption from the perspective of both patients receiving and medical professionals provid...
In total, 2 nationwide questionnaire surveys were conducted. The first survey, targeting both patients and healthy individuals, screened approximately 40,000 participants among 13 million people. The ...
The response rates among patients and healthy individuals targeted for the screening and main surveys were 92.5% (36,998/40,000) and ˃80% (1312/1478, 88.77%; 1281/1522, 84.17%; 404/478, 84.5%; and 222...
Our nationwide surveys provided insights into the current status of online medical care in Japan and simultaneously identified several problems and issues related to it, which will be useful in promot...
Despite the growing understanding of the carcinogenesis of pelvic high-grade serous carcinoma (HGSC) of the ovary and peritoneum and its precursor lesion serous tubal intraepithelial carcinoma (STIC),...
A questionnaire containing 21 questions was developed to explore the clinical experience with patients with the diagnosis of STICs and the diagnostic, surgical and histopathological approaches in Germ...
131 questionnaires (response rate 24.3%) were included in this survey. 45.8% of the respondents had treated one to three STIC patients during their career. 75.6% of the respondents performed opportuni...
Our survey highlights significant inconsistency in the management of patients with STIC. Prospective data are urgently needed to elucidate the clinical impact of a STIC lesion and its clinical managem...
Management of a clinical condition is patient centric. Interdisciplinary coordination plays an influential role in patient management. Pharmacology deals with the study of drugs. Clinical pharmacology...
We set up a survey to assess the perceptions of clinical pharmacologists (CPs) regarding their roles and about clinical pharmacology courses in India. The survey was administered via a Google question...
Respondents to the questionnaire were working as CPs. They were either postgraduate in pharmacology (MD pharmacology (doctor of medicine in pharmacology) 60.2%) or had a super-specialization degree in...
All the CPs opined that training during the postgraduation course was not sufficient to be qualified as CP. There was no consensus among the CPs on the benefit of existing certification courses in cli...
Response to survey questionnaires is vital for social and behavioural research, and most analyses assume full and accurate response by participants. However, nonresponse is common and impedes proper i...
To describe psychometric validation of the newly developed Advanced Practice Nurse Task Questionnaire....
Cross-sectional quantitative study....
The development of the questionnaire followed an adapted version of the seven steps described in the guide by the Association for Medical Education in Europe. A nationwide online survey tested the con...
We received 222 questionnaires between January and September 2020. The factor analysis produced a seven-factor solution as suggested in Hamric's model. However, not all item loadings aligned with the ...
A precise assessment of advanced practice nurse tasks is crucial in clinical practice and in research as it may be a basis for further refinement, implementation and evaluation of roles....
The Advanced Practice Nurse Task Questionnaire is the first valid tool to assess tasks according to Hamric's model of competencies independently of the role or the setting. Additionally, it distinguis...
The STARD 2015 guideline was used to report the study....
No patient or public contribution....
Chronic diseases are characterized by high incidence, long-term medication, and complex types of medication. There are also many corresponding medication therapy management (MTM) applications on the m...
From August 2019 to December 2019, we created a questionnaire to have knowledge of user needs, preferences, and expectations for MTM applications among 302 chronic patients in Hunan, Guangdong, and ot...
A total of 260 (86.09%) out of 302 patients the respondents were willing to use the MTM applications of chronic disease. The independent influencing factors for using the MTM applications were long-te...
The participants are willing to use MTM applications of chronic disease, with a preference for the WeChat applet. Patients tended to use MTM applications if they had a long-term medication history or ...